BIOMODE 2, S.A.

Their core work

BIOMODE 2 is a Portuguese diagnostics SME based in Braga that develops rapid diagnostic kits for detecting pathogen bacteria. Their core commercial product, the Probe4@ Rapid Diagnostic Kit, is designed to diagnose bacterial infections earlier and more accurately than conventional methods. They work at the intersection of biosensor technology, microfluidics, and lab-on-a-chip engineering, applying these to clinical diagnostics and infection control. Their participation in a European training network on host-pathogen adhesion signals that they also contribute real-world diagnostic tools to academic research partnerships.

What they specialise in

How they've shifted over time

BIOMODE's two H2020 projects both began in 2018, which means there is no meaningful temporal evolution to trace within this dataset — the keyword landscape from the early period covers biosensors, pathogens, and microfluidics, and the second half of the project list carries no additional keywords. What can be said is that in 2018 they pursued two parallel tracks simultaneously: commercial product validation via an SME Phase 1 grant, and scientific credibility via a large MSCA training network. Whether their focus has shifted after 2018 is not visible in this data.

BIOMODE entered H2020 with a clear commercial product and academic network simultaneously in 2018, suggesting a company preparing to scale — but their H2020 track record is too thin to confirm whether that trajectory continued post-2018.

How they like to work

BIOMODE operates in both roles: as coordinator for their own SME grant (a small, self-focused feasibility study) and as a partner in a large MSCA training network with 14 consortium members across 7 countries. The ViBrANT participation indicates they can plug into complex academic consortia as an industry partner bringing real diagnostic tools to research. For potential collaborators, this suggests they are comfortable in both a leadership seat and a specialist supporting role.

BIOMODE has worked with 14 unique consortium partners across 7 countries, almost entirely through the ViBrANT MSCA-ITN network. Their network is European in scope but was built through a single large training project rather than sustained multi-project partnerships.

What sets them apart

BIOMODE is one of very few Portuguese SMEs active at the convergence of point-of-care diagnostics, biosensors, and microfluidics with a proprietary commercial product (Probe4@) already in development. Their dual position — holding an SME Phase 1 grant for their own product while contributing to a pan-European academic training network — means they combine commercial urgency with access to frontier science. For a consortium looking for an industry partner that brings both a real product and pathogen biology expertise, BIOMODE fills a gap that pure research labs cannot.

Highlights from their portfolio

• Biomode
  As coordinator of their own SME Phase 1 grant, this project is direct evidence of a commercially-ready diagnostic product (Probe4@) with EU-validated feasibility.
• ViBrANT
  Participation in a 2018-2022 MSCA Innovative Training Network confirms BIOMODE's standing as an industry partner within a competitive Europe-wide academic consortium focused on host-pathogen adhesion.